Stafford MP, Jeremy Lefroy has joined other Members of Parliament in urging the NHS and Vertex pharmaceuticals to reach an agreement to allow access to essential precision drug Orkambi.
Jeremy attended a parliamentary event at the Houses of Parliament on the afternoon of Monday, 19th November.
People with CF have been waiting for three years for access to Orkambi, a treatment manufactured by Vertex Pharmaceuticals. The medicines are the first to treat the root cause of cystic fibrosis and have been shown to slow health deterioration and reduce the need for frequent hospitalisation. Without access to these medicines, people will inevitably suffer more rapid decline into debilitating illness, and in the worst cases, loss of life due to respiratory failure.
In North America, Europe, and Australia, 75,000 people live with cystic fibrosis with more than 12% of these people resident in the UK. Combination therapies manufactured by Vertex are the next generation of medicines.
Commenting, Jeremy said: “My constituents whose lives are affected by cystic fibrosis and others across the UK require immediate access to the most advanced medicines to manage this extremely serious condition. People with cystic fibrosis should be able to live full, healthy lives for as long as possible. There are drugs available today to help them achieve that and they are currently being denied access. I would therefore urge both Vertex and the NHS to move forward to facilitate access to these essential medicines as soon as possible.”